Loading company…
MindRank AI develops AI-based drug discovery platforms and drug candidates.
Founded in 2020 and based in Hangzhou, MindRank AI provides AI-assisted drug design platforms to pharmaceutical companies and develops its own drug pipeline. Its Molecule Arts Platform integrates biological, chemical, computational, and clinical data; candidates include MDR-001 for obesity and type 2 diabetes. In July 2026, the company raised USD 52 million in Series B funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in